Recruiting NCT04777175
A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: immunity therapy.
- Who it may be relevant to
- Registry conditions: Non Small Cell Lung Cancer. Basic parameters: 18 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
In advanced non-small cell lung cancer, there will be some rare mutations, such as ALK, KRAS, etc. The efficacy of these immunotherapies on these different rare mutations has not been reported. Therefore, we conducted this retrospective clinical study to explore the efficacy of immunotherapy for different rare mutations.
Interventions
- Drug immunity therapy
The patient receives immunotherapy
Primary outcome measures
- PFS [Time frame: January 2021- January 2021 (1 year)]
Eligibility criteria
Inclusion criteria
- 1.Diagnosed as advanced non-small cell lung cancer
- 2.Confirmed as KARS, ALK, ERBB2, MET, RET, BRAF mutation
Exclusion criteria
- The patient is diagnosed with small cell lung cancer
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 2 centers
- Hunan Cancer Hospital — Changsha
- Hunan Cancer hospital — Changsha
Identifiers
NCT: NCT04777175 · IRMLC